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Abnormal electrocardiograms (ECG) are associated with increased risk of arrhythmias and sudden 
cardiac death. We aimed to investigate the prevalence and associated risk factors of prolonged QTc 
and major ECG abnormalities, in persons living with HIV (PLWH) and uninfected controls.  
DESIGN 
PLWH aged ≥40 were recruited from the Copenhagen comorbidity in HIV infection (COCOMO) 
study and matched on sex and age to uninfected controls from the Copenhagen General Population 
Study. 
METHODS 
ECGs were categorized according to Minnesota Code Manual of ECG Findings definition of major 
abnormalities. A QT interval corrected for heart rate (QTc) >440ms in males and >460ms in females 
was considered prolonged. Pathologic Q-waves were defined as presence of major Q-wave 
abnormalities.  
RESULTS 
ECGs were available for 745 PLWH and 2,977 controls. Prolonged QTc was prevalent in 9% of 
PLWH and 6% of controls, p=.052. Pathologic Q-waves were more common in PLWH (6%) than in 
controls (4%), p=.028. There was no difference in prevalence of major ECG abnormalities between 
PLWH and controls, p=.987. 
In adjusted analyses, HIV was associated with a 3.6ms[1.8-5.4] longer QTc interval, p<.001, and HIV 
was independently associated with prolonged QTc (adjusted odds ratio: 1.59 [1.14-2.19]), p=.005. 
HIV was borderline associated to pathologic Q-waves after adjusting, p=.051. 
CONCLUSION 
HIV was associated with higher odds ratio of prolonged QTc after adjustment for cardiovascular risk 
factors, but analyses were not adjusted for QT-prolonging medication. Although evidence indicated 
more pathologic Q-waves in PLWH, the risk seemed to be associated mainly with an adverse risk 
profile.  
Keywords HIV; ECG; EKG; QT interval; Abnormalities; Cardiovascular disease; 
Comorbidities 
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BACKGROUND 
Previously, major electrocardiographic (ECG) abnormalities, including atrial fibrillation 
(AF), have been shown to be both prevalent and to carry a poor prognosis in persons living 
with HIV (PLWH)1–3. Similarly, prolonged corrected QT interval (QTc) is common among 
PLWH and associated with malignant arrhythmias and sudden cardiac death (SCD)4, but few 
studies have compared the prevalence of prolonged QTc in PLWH and the uninfected 
population5,6. Previous studies have included treatment naïve patients, patients from high risk 
populations, and patients with advanced HIV disease5–8. Thus, the effects of HIV on QTc 
may be confounded by an adverse risk profile with excess smoking, inflammation, and 
comorbidity (e.g structural heart disease) among PLWH9–13. Furthermore, use of QT-
prolonging drugs may differ in PLWH14. Thus, to describe the effect of HIV infection on 
ECG abnormalities and prolonged QTc, a well-characterized population of PLWH and 
comparable uninfected controls is needed.  
We aimed to determine the prevalence and associated risk factors of prolonged QTc and 
major electrocardiographic abnormalities among well-treated PLWH and uninfected controls 
and to determine if HIV is independently associated with prolonged QTc and/or major 
electrocardiographic abnormalities in PLWH. We hypothesized that HIV would be 
independently associated with prolonged QTc and major ECG abnormalities.  
METHODS 
Study populations and demographics 
PLWH were recruited from the Copenhagen Co-morbidity in HIV Infection (COCOMO) 
Study (NCT02382822). The COCOMO study is a non-interventional cohort study which 
assess the burden and pathogenesis of non-AIDS comorbidities in PLWH. The procedures for 
recruitment and data collection have been described elsewhere9. 
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Uninfected controls were included from the Copenhagen General Population Study (CGPS), 
a non-interventional general population study15. All participants in COCOMO and a subset of 
CGPS participants older than 40 years of age had an electronic ECG recorded. COCOMO 
participants older than 40 were frequency matched by age and sex (1:4) to participants from 
CGPS. 
Identical questionnaires were used to collect information regarding medical history, smoking, 
alcohol consumption and use of medication. A physical exam including anthropometrics and 
blood pressure was performed by trained clinical staff. Measurements of high-sensitivity C-
reactive protein (hsCRP), LDL cholesterol (LDL) and glucose were done16. HIV-related 
characteristics were obtained through review of medical records.  
We defined hypertension as current anti-hypertensive treatment and/or systolic ≥140mmHg 
and/or diastolic blood pressure ≥90mmHg9. Body Mass Index (BMI) was defined according 
to the WHO classification17 and dyslipidemia was defined as LDL ≥160mg/dl (4.14mM) 
and/or current lipid lowering treatment9.  
ECG recording 
ECGs were recorded by trained  using a CardioSoft electrocardiograph Module and 
CardioSoft v6.7 Diagnostic System (GE Healthcare) software.  
A resting ECG was only recorded and stored when all lead readings were calibrated, and no 
muscular interference was visible. Recorded ECGs were transferred to the MUSE Cardiology 
Information System (GE Healthcare, Wauwatosa, WI) in standard 12SL output format.  
ECG variables 
ECGs were coded according to the Minnesota code manual for electrocardiographic findings 
(MC)18. AF, atrioventricular (AV) conduction abnormalities and length of intervals and 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
segments were coded using v.21 of the validated Marquette 12SL algorithm4. We 
prespecified to use Bazett’s formula for QT interval correction. QT prolongation was defined 
as QTc >460ms for women and as QTc >450ms for men. Major prolongation was defined as 
QTc >480ms for both women and men19. Participants with a QRS duration of 120ms or more 
or with ventricular rates >100bpm, were not included in the analyses of the QT interval. 
Electrocardiographic abnormalities were classified as major abnormalities as suggested by 
MC and according to similar studies6,20(MC criteria in supplementary table 1 , 
http://links.lww.com/QAD/B517). All ECGs with major MC abnormalities were manually 
overread by a physician blinded to HIV status. Manually inspected ECGs of poor quality 
were excluded.  
Statistics 
Student's t tests or Mann–Whitney U tests were used for comparison of continuous data and 
χ2 tests or Fisher’s exact test were used for categorical data.  
We assessed whether HIV was associated with prolonged QTc or major MC abnormalities 
using multivariable logistic regression analyses adjusted for a prespecified model. The model 
included age, sex, hypertension, diabetes, dyslipidemia and smoking status. We further tested 
if prespecified major MC abnormalities 1) pathologic Q-waves; 2) intraventricular blocks 
(IV-blocks); 3) AF were associated with HIV or other independent variables. We investigated 
the association of HIV and independent variables to QTc length in multiple linear regression 
adjusted for the same prespecified model. Within PLWH, we tested whether HIV-related 
characteristics including current cART use (protease inhibitors, Efavirenz and Rilpivirine) 
were associated with prolonged QTc or major MC abnormalities.  
A P-value  .05 inferred statistical significance. All analyses were generated as available case 
analysis using SAS software v9.4 (SAS Institute, USA.) 
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RESULTS 
Of 3,735 coded ECGs, 484 met an MC criterion for major abnormality. On manual 
overreading of these, 13 (2%) were excluded due to inadequate quality and 32 (7%) were 
reclassified as no abnormality. ECGs were available for 745 PLWH and 2,977 controls 
(Supplementary Figure 1, http://links.lww.com/QAD/B517). 
Patient characteristics are listed in Table 1.  
Prolonged QTc among PLWH and uninfected controls 
In PLWH and controls, mean QTc was 422ms (95% confidence interval[CI]: [421-424] and 
421ms [420-421], respectively, p=.049 (Fig. 2). After adjusting, HIV was associated with 
3.6ms [1.8-5.4] longer QTc interval, p<.001. Furthermore, age, female sex, hypertension, 
smoking, diabetes, obesity and hsCRP were associated with longer QTc (table 2). 
Prolonged QTc was found in 9% of PLWH and in 6% of the controls, p =.052, corresponding 
to a crude odds ratio (OR) of 1.35 [1.00-1.83]. Major prolongation of the QTc was present in 
1.3% of PLWH and 0.5% of controls, p=.021, but was not associated with HIV in adjusted 
analyses, p=.168 (Supplementary Figure 2, http://links.lww.com/QAD/B517).  
After adjusting, HIV was independently associated with prolonged QTc with an adjusted 
odds ratio (aOR) of 1.59 [1.14-2.19], p=.005. Furthermore, older age, hypertension, and 
pathologic Q-waves were associated with prolonged QTc (table 2).  
Prolonged QTc among PLWH 
In analyses restricted to PLWH, current CD4, CD4 nadir <200, CD8, CD4:CD8 ratio, 
previous AIDS defining condition, current use of protease inhibitor, Efavirenz or Rilpivirine, 
and illicit drug use were not independently associated with prolonged QTc.  
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Major abnormalities among PLWH and uninfected controls 
A major MC abnormality was present in 88 (12%) of PLWH and in 351 (12%) of controls, 
p=.987. Pathologic Q-waves were found in 45 (6%) and 124 (4%) of PLWH and controls, 
respectively, corresponding to a crude odds ratio (OR) of 1.48 [1.04-2.10], p=.028. There was 
no difference in prevalence of IV-block p=.839, or AF p=.285, (Supplementary Table 2, 
http://links.lww.com/QAD/B517). 
HIV was not independently associated with major MC abnormalities when adjusted for 
confounders, p=.141, or with any specific major MC abnormality, including AF (p=.254) or 
IV-blocks (p=.723). However, a borderline association with pathologic Q-waves was found 
(p=.051). In PLWH, but not controls, pathologic Q-waves were also associated with hsCRP 
(aOR per 10 mg/L increase: 1.36 [1.02-1.83]). 
Discussion 
PWLH had a higher prevalence of prolonged QTc compared to uninfected controls, and HIV 
was independently associated with prolonged QTc after adjusting for traditional risk factors, 
though we did not adjust for use of QT prolonging medications. cART regimen was not 
associated with prolonged QTc. Prevalence of pathologic Q-waves was higher among 
PLWH, but the association was attenuated when adjusting for traditional risk factors, 
suggesting that traditional risks may carry some of the excess risk. 
Prolonged QTc is independently associated with malignant ventricular arrhythmias and 
SCD4, and has been reported to be higher among PLWH in both treatment naïve8 and patients 
on cART14,21. Prevalence estimates differ markedly and ranges from 5% to more than 40%, 
depending on the investigated population. Most prior studies are limited by size, have lacked 
comparable controls or have recruited patients from highly selected populations8,14,21–23. In 
the HIV-HEART study, prolonged QTc was present in 21% among PLWH vs 3.5% among 
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the uninfected14. In the MACS cohort, there was no difference in prevalence of prolonged 
QTc between PLWH and controls (3% in both groups), but the QTc interval was 4ms longer 
among PLWH when adjusting for confounders21.The association was attenuated by 
adjustment for inflammatory markers. The prevalence of prolonged QTc in our study was 9% 
and in between the estimates from the HIV-HEART and MACS cohorts and our data confirm 
the association between inflammation and QTc in other studies11,21. hsCRP is, however, a 
crude marker of inflammation and further studies should explore the impact of different 
inflammatory pathways in PLWH and uninfected. 
We expected major MC abnormalities to be prevalent among PLWH and while more than 
one in ten PLWH did have major MC abnormalities, prevalence was not higher than among 
the controls, as anticipated by prior studies without controls2,6. HIV and pathologic Q-waves 
were associated in univariable analyses, but this association was attenuated to borderline 
significance after adjusting for traditional risk factors, suggesting an adverse risk profile 
among PLWH9,24 to contribute. PLWH have increased risk of heart failure and 
cardiomyopathies12, and studies of intraventricular conduction defects in PLWH have found 
QRS-duration to be associated with use of protease inhibitors25. We therefore hypothesized 
HIV infection to be associated with IV-block, but distribution of IV-blocks was similar in 
PLWH and controls and there was no association to specific cART regimens. A recent 
analysis of five thousand PLWH did not report AF to be more prevalent than in controls, but 
found low CD4 nadir to be predictive of AF3. In an indirect comparison to the Framingham 
study, a study found higher incidence of AF in PLWH aged 55-75, but they did not account 
for differences in risk factors2. We found a low (1%) prevalence of AF in PLWH and controls 
and comparable to participants in Framingham26. The few cases did not allow us to 
investigate associations between AF and CD4 nadir.  
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Common causes of acquired QTc prolongation include use of methadone and antiarrhythmic, 
antibiotic, and psychotropic medications which may all be more commonly used among 
PLWH27,28. Limitations to the study, thus, included inability to adjust for QT prolonging 
medication use, and although MC criteria are validated against clinical outcomes, other 
categorizations may have produced different estimates of abnormalities. However, ECGs 
were recorded on the same device and grouped according to the same criteria, interval and 
segment lengths were automatically measured and all ECG evaluations were blinded to HIV 
status. Thus, a different categorization would likely have affected both populations equally. 
Additionally, the cross-sectional design prevents us from drawing conclusions regarding 
causality.  Strengths of the study include the size and the uniform approach to data collection. 
In conclusion, well-treated PLWH had a higher prevalence of prolonged QTc and pathologic 
Q-waves and ECG evidence of previous myocardial infarction than uninfected controls. 
Adjusting for risk factors attenuated the association between HIV and pathologic Q-waves, 
but HIV was independently associated with prolonged QTc. hsCRP was marginally 
associated with QTc length and pathologic Q-waves (but not prolonged QTc)  in PLWH. 
Further studies are needed to explore the impact of prolonged QTc on clinical outcomes in 
PLWH.  
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Table 1. Demographic characteristics of persons living with HIV and uninfected 
controls 
Demographic characteristics 
 PLWH 745 Controls 2,977 
Men, n (%) 641 (86) 2,481 (83) 
Age, mean (SD) 54 (9) 56(9) 
Origin 
• Scandinavian 
• Other European 
• Middle East and Indian subcontinent 
• Other 
 
571 (77) 
78 (11) 
12 (2) 
82 (11) 
 
2,782 (93) 
130 (4) 
19 (1) 
9 (0.3) 
Smoking status, n (%) 
• Current 
• Former 
• Never 
 
195 (26) 
292 (39) 
257 (35) 
 
365 (12) 
1,284 (43) 
1,303 (44) 
Pack years median (IQR) 20 (7-34) 13 (3-26) 
Hypertension, n (%) 348 (47) 1,861 (63) 
Diabetes, n (%) 37 (5) 123 (4) 
Obese (BMI>30) 73 (10) 538 (18) 
LDL 2.8 (1) 3.2 (1) 
Statin 120 (16) 388 (13) 
Dyslipidemia 71 (10) 473 (16) 
HIV specific characteristics   
Mode of transmission   
• MSM   520 (70) - 
• Heterosexual 161 (22) - 
• IDU  8 (1.1) - 
• Other or unknown  56 (7.5) - 
Current CD4 count, CD4/µL, median (IQR) 510 (670-
870) 
- 
• <200 CD4/µL, n (%) 11 (1.5) - 
• 200–349 CD4/µL, n (%) 45 (6.0) - 
• 350-499 CD4/µL, n (%) 109 (15) - 
• >500 CD4/µL, n (%) 572 (77) - 
CD4 nadir <200/µL, n (%) 327 (44) - 
HIV RNA <50 copies/mL, n (%) 706 (95) - 
Current cART use, n (%) 732 (98) - 
• Rilpivirine use, n (%) 16 (2.3) - 
• Efavirenz use, n (%)  217 (30) - 
• Protease inhibitor use, n (%) 222 (30) - 
IDU: Injecting drug use; MSM:Men who have sex with men;  
Number of missing data per variable: Origin: 39; Smoking status:26; Hypertension:48; 
Diabetes:23; Obese:7; Dyslipidemia:127 
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Table 2. Association of corrected QT interval to independent risk factors. 
Association of corrected QT interval to independent risk factors ※  
QTc length Prolonged QTc 
 β-
coefficient 
P Adjusted β-
coefficient 
P OR  P aOR P 
HIV yes vs. no 1.9 [0.0-
3.7] 
.049 3.6 [1.8-5.4] <.001 1.35 
[1.00-
1.83] 
.052 1.59 
[1.14 
2.19] 
.005 
Age* 3.0 [2.3-
3.7] 
<.001 2.9[2.1-3.7] <.001 1.54 
[1.34-
1.77] 
<.001 1.45 
[1.25-
1.67] 
<.001 
Male sex -8.3 [-10.2-
(-)6.5] 
<.001 -11.2 [-13.1-(-
)9.2] 
<.001 1.03 
[0.72-
1.46] 
.888 0.72 
[0.51-
1.06] 
.086 
Hypertension 6.0 [4.6-
7.4] 
<.001 5.8 [4.3-7.3] <.001 2.34 
[1.72-
3.18] 
<.001 1.94 
[1.41 
2.71] 
<.001 
Current smoker 1.6 [-0.4-
3.5] 
.114 2.6 [0.6-4.5] .010 1.14 
[0.81-
1.62] 
.453 1.26 
[0.87-
1.79] 
.212 
Dyslipidemia 1.1 [-0.9-
3.1] 
.297 1.4 [-0.5-3.4] .149 1.12 
[0.78-
1.60] 
.541 1.18 
[0.81-
1.68] 
.368 
Diabetes 1.4 [0.74-
2.76] 
.289 4.4 [0.9-8.0] .014 2.01 
[1.20-
3.35] 
.007 1.60 
[0.91-
2.66] 
.086 
hsCRP** 2.3 [0.8-
3.9] 
.002 1.5 [0.02-3.0] .046 1.14 
[0.90-
1.36] 
.196 1.07 
[0.82-
1.29] 
.507 
Heavy Drinker¥ 1.6 [0.1-
3.2] 
.040 1.0 [-0.6-2.6] .227 1.17 
[0.89-
1.55] 
.263 0.94 
[0.70 
1.27] 
.702 
Obesity¥¥ 4.6 [2.7-
6.5] 
<.001 3.0 [1.1-5.0] .002 1.43 
[1.04-
1.98] 
.027 1.21 
[0.85-
1.68] 
.287 
Pathologic Q-waves 6.9 [3.3-
10.5] 
.001 5.6 [2.0-9.3] .002 2.66 
[1.66-
4.28] 
<.001 2.24 
[1.33-
3.64] 
.002 
Scandinavian (yes 
vs. no) 
5.3 [2.6-
8.0] 
<.001 3.4 [0.7-6.0] .014 1.49 
[0.90-
2.47] 
.122 1.30 
[0.80-
2.25] 
.317 
※ Multiple linear regression analyses (left panel) and multivariable logistic analyses (right panel) with 95% 
confidence intervals. Model Adjusted for Age, Sex, Hypertension, Smoking status, Dyslipidemia and 
Diabetes. 
*per decade older  
**per 10 mg/L increase 
¥defined as 14 or more units of alcohol per week 
¥¥defined as BMI >30kg/m2 
OR: odds ratio; aOR: adjusted odds ratio; QTc: QT interval corrected for heart rate using Bazett’s formula 
(QT/RR1/2); prolonged QTc defined as QTc >460ms for women and as QTc >450ms for men 
 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
